


## Accepted Manuscript

Title: Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation

Authors: Yasmin Abaza, Juliana E. Hidalgo-Lopez, Srdan Verstovsek, Elias Jabbour, Farhad Ravandi, Gautam Borthakur, Zeev Estrov, Yesid Alvarado, Jan Burger, Heather Schneider, Kelly A. Soltysiak, Yue Wei, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero



PII: S0145-2126(18)30210-8  
DOI: <https://doi.org/10.1016/j.leukres.2018.09.004>  
Reference: LR 6036

To appear in: *Leukemia Research*

Received date: 15-6-2018  
Revised date: 28-8-2018  
Accepted date: 13-9-2018

Please cite this article as: Abaza Y, Hidalgo-Lopez JE, Verstovsek S, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Alvarado Y, Burger J, Schneider H, Soltysiak KA, Wei Y, Kantarjian HM, Bueso-Ramos CE, Garcia-Manero G, Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation, *Leukemia Research* (2018), <https://doi.org/10.1016/j.leukres.2018.09.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# **Phase I Study of Ruxolitinib in Previously Treated Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome with Evidence of NF-kB Activation**

Yasmin Abaza<sup>1</sup>, Juliana E. Hidalgo-Lopez<sup>2</sup>, Srdan Verstovsek<sup>1</sup>, Elias Jabbour<sup>1</sup>, Farhad Ravandi<sup>1</sup>, Gautam Borthakur<sup>1</sup>, Zeev Estrov<sup>1</sup>, Yesid Alvarado<sup>1</sup>, Jan Burger<sup>1</sup>, Heather Schneider<sup>1</sup>, Kelly A. Soltysiak<sup>1</sup>, Yue Wei<sup>1</sup>, Hagop M. Kantarjian<sup>1</sup>, Carlos E. Bueso-Ramos<sup>2</sup>, and Guillermo Garcia-Manero<sup>1\*</sup>

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.<sup>1</sup>

Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.<sup>2</sup>

**Short Title:** Ruxolitinib in Myelodysplastic Dysplastic Syndromes

**Abstract Word Count:** 247

**Text Word Count:** 2995

**Figure/Table Count:** 7

**\*Address correspondence to:**

Guillermo Garcia-Manero, M.D.  
Department of Leukemia  
University of Texas  
MD Anderson Cancer Center  
1515 Holcombe Blvd  
Houston, TX 77030  
Fax: 713-745-4612  
Phone: 713-745-3428  
E-mail: ggarciam@mdanderson.org

Download English Version:

<https://daneshyari.com/en/article/11030820>

Download Persian Version:

<https://daneshyari.com/article/11030820>

[Daneshyari.com](https://daneshyari.com)